皓元医药
(688131)
| 流通市值：198.31亿 | | | 总市值：198.31亿 |
| 流通股本：2.13亿 | | | 总股本：2.13亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,646,278,143.58 | 1,647,974,323.92 | 728,650,826.78 | 2,876,896,205.58 |
| 营业收入 | 2,646,278,143.58 | 1,647,974,323.92 | 728,650,826.78 | 2,876,896,205.58 |
| 二、营业总成本 | 2,175,287,748.84 | 1,384,319,166.19 | 617,062,250.99 | 2,442,468,503.31 |
| 营业成本 | 1,301,632,070.33 | 811,400,587.07 | 346,654,921.91 | 1,521,776,147.68 |
| 税金及附加 | 13,926,982.14 | 8,258,236.18 | 3,431,956.02 | 17,956,156.6 |
| 销售费用 | 260,970,646.83 | 169,876,686.11 | 82,392,532.56 | 278,175,670.89 |
| 管理费用 | 291,462,985.88 | 191,085,183.59 | 92,556,487.15 | 323,909,542.57 |
| 研发费用 | 210,654,968.8 | 133,730,617.4 | 64,509,286.99 | 237,617,348.41 |
| 财务费用 | 96,640,094.86 | 69,967,855.84 | 27,517,066.36 | 63,033,637.16 |
| 其中:利息费用 | 40,182,858.7 | 25,582,273.33 | 12,322,721.99 | 53,800,018.86 |
| 其中:利息收入 | 15,482,612.5 | 9,880,816.43 | 4,946,228.64 | 14,105,218.19 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 433,543.56 | 282,760.38 | - | 73,589.04 |
| 加:投资收益 | -678,756.04 | 311,085.31 | -254,508.65 | -15,966,771.96 |
| 资产处置收益 | 393,258.67 | 293,523.27 | -98,102.78 | 793,500.41 |
| 资产减值损失(新) | -132,749,092.6 | -79,886,893.93 | -38,413,809.17 | -134,087,756.31 |
| 信用减值损失(新) | -18,440,798.1 | -12,996,607.91 | -3,232,855.14 | -19,754,490.71 |
| 其他收益 | 27,503,859.55 | 21,869,177.7 | 4,599,273.1 | 31,267,495.44 |
| 四、营业利润 | 347,452,409.78 | 193,528,202.55 | 74,188,573.15 | 296,753,268.18 |
| 加:营业外收入 | 451,258.79 | 326,030.51 | 193,606.63 | 1,707,123.78 |
| 减:营业外支出 | 1,854,631.1 | 1,260,943.51 | 239,878.72 | 22,684,833.29 |
| 五、利润总额 | 346,049,037.47 | 192,593,289.55 | 74,142,301.06 | 275,775,558.67 |
| 减:所得税费用 | 53,081,818.61 | 30,497,371.32 | 11,135,872.21 | 44,130,127.34 |
| 六、净利润 | 292,967,218.86 | 162,095,918.23 | 63,006,428.85 | 231,645,431.33 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 292,967,218.86 | 162,095,918.23 | 63,006,428.85 | 231,645,431.33 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 308,819,915.61 | 171,200,366.68 | 67,840,532.33 | 239,806,806.41 |
| 少数股东损益 | -15,852,696.75 | -9,104,448.45 | -4,834,103.48 | -8,161,375.08 |
| 扣除非经常损益后的净利润 | 288,840,391.34 | 154,929,953.41 | 66,305,583.59 | 247,127,876.08 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.45 | 0.81 | 0.32 | 1.13 |
| (二)稀释每股收益 | 1.45 | 0.81 | 0.32 | 1.13 |
| 八、其他综合收益 | -10,371,428.51 | -6,350,002.37 | -3,706,137.65 | -996,967.42 |
| 归属于母公司股东的其他综合收益 | -10,371,428.51 | -6,350,002.37 | -3,706,137.65 | -996,967.42 |
| 九、综合收益总额 | 282,595,790.35 | 155,745,915.86 | 59,300,291.2 | 230,648,463.91 |
| 归属于母公司股东的综合收益总额 | 298,448,487.1 | 164,850,364.31 | 64,134,394.68 | 238,809,838.99 |
| 归属于少数股东的综合收益总额 | -15,852,696.75 | -9,104,448.45 | -4,834,103.48 | -8,161,375.08 |
| 公告日期 | 2026-10-30 | 2026-08-27 | 2026-04-30 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |